25 recruiting, 4 active not recruiting, 4 completed, 2 not yet recruiting. 14 Phase 2, 11 Phase 1, 3 Not applicable, 3 Phase 3.
Follow Glioblastoma, IDH-wildtype: new trials by email Literature Review of Glioblastoma, IDH-wildtype trials Research Report on Glioblastoma, IDH-wildtype
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy, Cemiplimab, Chemotherapy - Glioblastoma, Glioblastoma, IDH-wildtype | Phase 2 | Not yet recruiting | Washington University School of Medicine | 99 | 2026-11-30 | 2026-10-20 |
| Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma Archive Sample Retrieval, Biospecimen Collection, Chest Radiography - Glioblastoma, IDH-Wildtype | Phase 2 | Recruiting | Mayo Clinic | 60 | 2026-08-28 | 2026-10-15 |
| GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography - Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Recruiting | Mayo Clinic | 36 | 2026-08-03 | 2026-10-01 |
| Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma | Phase 3 | Recruiting | NRG Oncology | 398 | 2026-07-16 | 2026-09-10 |
| Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas Biospecimen Collection, Eflornithine, Lumbar Puncture - Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 33 | 2026-06-23 | 2026-06-24 |
| A Study of 177Lu-PSMA-617 in People With Gliomas Temozolomide, 177Lu-PSMA-617, 68Ga-PSMA-PET scan/ MRI - Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4) | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2025-10-27 | 2026-06-04 |
| Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma Best Practice, Biospecimen Collection, Dietary Intervention - Glioblastoma, IDH-Wildtype, WHO Grade 4 Glioma | Not applicable | Recruiting | Mayo Clinic | 116 | 2025-07-29 | 2026-08-17 |
| ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801 - Glioblastoma, Glioblastoma, IDH-Wildtype | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 50 | 2025-07-28 | 2026-09-18 |
| Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma Temozolomide, Lomustine - Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma | Phase 3 | Recruiting | Vastra Gotaland Region | 200 | 2025-02-01 | 2026-04-13 |
| Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter Ropidoxuridine - Glioblastoma, IDH-wildtype | Phase 2 | Terminated | Shuttle Pharmaceuticals, Inc. | 30 | 2024-09-02 | 2025-12-18 |
| WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy - Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma | Phase 2 | Recruiting | Northwestern University | 39 | 2024-05-22 | 2026-07-22 |
| Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide Metformin, Radiation IMRT, Temozolomide - Glioblastoma, IDH-wildtype | Phase 2 | Recruiting | Hopital Foch | 640 | 2024-05-10 | 2025-11-21 |
| Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Fluciclovine F18, Gadolinium-Chelate - Glioblastoma, IDH-Wildtype | Phase 2 | Recruiting | ECOG-ACRIN Cancer Research Group | 100 | 2024-04-11 | 2026-08-18 |
| Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma Atorvastatin 20mg - Glioblastoma, IDH-wildtype | Phase 2 | Recruiting | Tianjin Medical University General Hospital | 50 | 2024-04-01 | 2024-03-25 |
| Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma hypofractionated stereotactic radiotherapy, Stereotactic biopsy, resection - Glioblastoma, Glioblastoma Multiforme | Phase 1 | Recruiting | Hospital San Carlos, Madrid | 12 | 2024-03-21 | 2024-05-16 |
| Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma Biological biomarker analysis - Glioblastoma, IDH-wildtype | Not applicable | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 120 | 2024-02-29 | 2025-03-13 |
| Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma Metformin - Glioblastoma, IDH-wildtype, Metformin | Phase 2 | Recruiting | University of Milano Bicocca | 25 | 2024-02-12 | 2025-07-25 |
| Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NEO212 Oral Capsule, Ipilimumab, Pembrolizumab - Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype | Phase 1 / Phase 2 | Recruiting | Neonc Technologies, Inc. | 134 | 2023-11-01 | 2026-09-24 |
| Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis Long term survival multimodal analysis - Pancreas Adenocarcinoma, Small-cell Lung Cancer | Recruiting | Cure 51 | 1020 | 2023-11-01 | 2023-12-07 | |
| Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma Eflornithine (Dose Level 1), Eflornithine (Dose Level 2), Eflornithine (Dose Level -1) - Glioblastoma, IDH-wildtype, Glioblastoma | Phase 1 | Recruiting | Orbus Therapeutics, Inc. | 66 | 2023-07-24 | 2025-06-25 |
Showing 20 of 36. Sign in to see all of them.
Glioblastoma (36) · Astrocytoma (12) · Glioma (7) · Brain Neoplasms (6) · Gliosarcoma (3) · Recurrence (3) · Carcinoma, Non-Small-Cell Lung (2) · Central Nervous System Neoplasms (2) · Lymphoma, Follicular (2) · Neoplasms (2) · Oligodendroglioma (2) · Small Cell Lung Carcinoma (2) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1)
Neoplasms by Histologic Type (36) · Neoplasms, Glandular and Epithelial (36) · Neoplasms, Nerve Tissue (36) · Neuroectodermal Tumors (36) · Neoplasms, Germ Cell and Embryonal (35) · Neoplasms, Neuroepithelial (35) · Neoplasms (34) · Glioma (29) · Astrocytoma (24) · Neoplasms by Site (8) · Brain Diseases (6) · Central Nervous System Diseases (6) · Nervous System Diseases (6) · Nervous System Neoplasms (6) · Central Nervous System Neoplasms (4)
Magnetic Resonance Spectroscopy (10) · Temozolomide (10) · Specimen Handling (8) · Radiation (5) · Drug Therapy (3) · Radiotherapy (3) · Surgical Procedures, Operative (3) · Transurethral Resection of Bladder (3) · Bevacizumab (2) · Carboplatin (2) · Eflornithine (2) · Ipilimumab (2) · Lomustine (2) · Metformin (2) · Nivolumab (2)
Mayo Clinic (5) · Jasper Gerritsen (4) · Northwestern University (3) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2) · Cure 51 (1) · ECOG-ACRIN Cancer Research Group (1) · Erasmus Medical Center (1) · Hopital Foch (1) · Hospital San Carlos, Madrid (1) · Istituto Oncologico Veneto IRCCS (1) · Jonsson Comprehensive Cancer Center (1) · Juan M Garcia-Gomez (1) · Memorial Sloan Kettering Cancer Center (1) · NRG Oncology (1) · National Cancer Institute (NCI) (1)
United States (24) · Belgium (5) · Germany (5) · Italy (5) · Netherlands (5) · Switzerland (5) · China (2) · France (2) · Spain (2) · Austria (1) · Canada (1) · Denmark (1) · Norway (1) · Puerto Rico (1) · Sweden (1)
Jasper Gerritsen, MD PhD (5) · Adam M Sonabend, MD (1) · Amy Heimberger (1) · Brandon Imber, MD (1) · Chunsheng Kang (1) · Daniel P Barboriak (1) · Gavin P Dunn (1) · Gelareh Zadeh, MD, PhD (1) · Giles W. Robinson, MD (1) · Howard Colman, MD, PhD (1) · Jian L Campian, MD, PhD (1) · Jiayi Huang (1) · John Boockvar, MD (1)
PMID 35552677, PMID 37142373, PMID 39260848, PMID 39724015
P30CA060553 (2), 2023 (1), R01CA279984 (1), U10CA180820 (1), U10CA180821 (1), UG1CA189867 (1)